751.95
Regeneron Pharmaceuticals Inc stock is traded at $751.95, with a volume of 487.19K.
It is down -2.41% in the last 24 hours and down -4.12% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$771.25
Open:
$765.15
24h Volume:
487.19K
Relative Volume:
0.50
Market Cap:
$79.06B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
18.00
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+0.44%
1M Performance:
-4.12%
6M Performance:
+34.73%
1Y Performance:
+9.66%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals Inc
|
752.25 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.00 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
846.37 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.51 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.15 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? - TradingView
Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cambiar Investors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cullen Frost Bankers Inc. - MarketBeat
Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook - simplywall.st
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha
Lbp Am Sa Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bernstein Adjusts PT on Regeneron Pharmaceuticals to $916 From $911, Maintains Outperform Rating - marketscreener.com
Compass Wealth Management LLC Buys Shares of 3,634 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sovran Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum - simplywall.st
Y Intercept Hong Kong Ltd Sells 24,556 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stoneridge Investment Partners LLC Buys Shares of 2,360 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teacher Retirement System of Texas Sells 2,558 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Eylea HD Progress and STEM Investment Push Means For Shareholders - simplywall.st
Oxbow Advisors LLC Takes $2.95 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Regeneron: Q4 Earnings PreviewWhy I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN) - Seeking Alpha
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines - Pharma Voice
The Truth About Regeneron Pharmaceuticals: Why Wall Street Can’t Stop Watching REGN - AD HOC NEWS
How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - Yahoo Finance
Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Weakness? - simplywall.st
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Regeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on Friday - MarketBeat
Bi Specific Antibodies Therapy Market Is Booming Worldwide | AbbVie • Regeneron Pharmaceuticals • Pfizer - openPR.com
2 Healthcare Stocks Poised for a Comeback in 2026 - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00 at Evercore ISI - MarketBeat
REGN: Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating | REGN Stock News - GuruFocus
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution - simplywall.st
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
2 Westchester County Teens Among 40 Regeneron Science Talent Search 2026 Finalists - Patch
40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan
58,906 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Rakuten Investment Management Inc. - MarketBeat
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - manilatimes.net
Seizert Capital Partners LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
(REGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Should You Be Excited for Regeneron (REGN)? - Insider Monkey
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - Yahoo Finance
Allstate Corp Makes New $2.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Expansion wave in Saratoga County, New York: Regeneron, GlobalFoundries, Soleno, LISSMAC and more - The Business Journals
Third retinal indication for Eylea 8mg approved in Europe - The Pharma Letter
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):